CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Signia is developing a drug platform that repurposes existing medications to create effective treatments for acute respiratory infections. By targeting the host's cellular response rather than specific pathogens, the approach aims to expedite drug development and improve treatment outcomes.
Pharma industry is facing the challenge of high-cost and time-consuming processes for de novo drug development (€1-2 billion and 10-17 years per marketed drug), also influenced by high failure rates (only 10% of drug candidates are approved for market entry).
As a result, an increasing number of firms seek alliances based on repurposing existing drugs for new indications to deliver the needed productivity increases, shifting the focus of R&D to smaller biotech companies.Among all infectious dise…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
